STERIS: Strong Quarter, Demanding Price

The Quarter in Context

For the three months ended September 30, 2026, STERIS reported revenue of $1.589 billion, gross profit of $710.8 million, operating income of $294.3 million, and net income attributable to shareholders of $213.7 million. Revenue rose 8.8% from $1.460 billion in the year-earlier quarter, while operating income increased 10.7% and net income rose 11.4%. These results indicate continued growth and modest operating leverage, although reported restructuring charges affected comparability.

Cash generation was less dynamic than accounting profit. Operating cash flow for the quarter was derived by subtracting the $367.1 million cumulative operating cash flow for April–June 2026 from the $656.1 million cumulative amount for April–September 2026. That calculation yields $289.0 million for July–September 2026, compared with $287.8 million in the year-earlier quarter, also derived from cumulative filings. Capital expenditure for the quarter was likewise derived from cumulative statements: $163.6 million through September 2026 less $87.5 million through June 2026, producing $76.1 million for July–September 2026.

The central tension is therefore not business performance but price. At $254.55 per share on November 6, 2026, STERIS had a market capitalization of $24.819 billion. That valuation recognizes a good operating franchise, but it also demands sustained growth, durable margins, disciplined acquisition integration, and limited debt-funded risk.

Business Model and Profit Engine

STERIS sells products and services that support patient care, with an emphasis on infection prevention. Healthcare providers, medical-device manufacturers, and pharmaceutical manufacturers are the principal payers. They buy consumables, capital equipment, installation, maintenance, repair, laboratory testing, outsourced reprocessing, process-validation support, and operating-room integration. The mix combines transactional product sales and capital-equipment orders with recurring or repeat service, consumable, maintenance, and reprocessing relationships.

The company reports three segments. Healthcare provides infection-prevention consumables, sterilizers, washers, endoscopy accessories, surgical tables, connectivity solutions, and related maintenance, repair, and outsourced reprocessing services. Applied Sterilization Technologies, or AST, provides contract sterilization and laboratory testing through a global facility network, plus sterilization equipment and controls. Life Sciences supplies aseptic-manufacturing consumables, maintenance, specialty services, sterilants, washers, decontamination systems, and high-purity water and steam generators.

In the latest quarter, product revenue was $816.9 million and service revenue was $771.7 million, meaning service represented slightly less than half of sales. Product cost of revenue was $410.0 million, leaving $406.9 million of product gross profit before any allocation beyond cost of revenue; service cost was $467.7 million, leaving $304.0 million of service gross profit. After total cost of revenue, gross profit was $710.8 million. Selling, general and administrative expense, research and development, and restructuring then reduced that to $294.3 million of operating income.

Analytical inference: the broad product-and-service portfolio can smooth demand because consumables and service utilization are linked to installed equipment and recurring healthcare activity. However, segment-level revenue, margins, capital intensity, and cross-subsidies are not available in the cited excerpts. Customer concentration is also only partially disclosed: no customer represented more than 10% of each segment’s fiscal 2026 revenue, but that does not establish low consolidated concentration or recurring revenue by cohort.

Pricing power cannot be quantified from the filing. Observable conditions that would weaken the profit engine include sustained price increases below input-cost inflation, falling procedure volumes, customer insourcing, loss of regulated product approvals, or service labor and facility costs rising faster than revenue. Capital expenditure is meaningful, and the filings do not separate maintenance from growth spending, so unit economics by product and installed base cannot be calculated.

Earnings Quality and Cash Conversion

Quarterly cash-flow calculations below subtract two reported cumulative statements. These are author calculations, not directly reported quarterly line items. Amounts are USD.

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items.

The $213.7 million quarterly net income translated into $289.0 million of derived operating cash flow, a healthy conversion at the consolidated level. Over the twelve months ended September 30, 2026, operating cash flow was $1.290 billion and capital expenditure was $352.5 million. Their difference is a $937.2 million accounting free-cash-flow proxy—operating cash flow minus capital expenditure—not normalized owner earnings.

The same-period arithmetic matters. The $76.1 million quarterly capital-expenditure figure is derived by subtracting the April–June 2026 cumulative $87.5 million from the April–September cumulative $163.6 million; it is not a separately reported quarterly line item. The resulting $212.9 million quarterly accounting free-cash-flow proxy is therefore calculated from two same-period standalone cash-flow operands.

Cash conversion was broadly stable rather than accelerating. Derived quarterly operating cash flow rose only 0.4%, even as quarterly net income rose 11.4%. Working-capital movements help explain the difference. During the six months ended September 30, 2026, receivables released $93.0 million of cash, but inventory consumed $99.6 million, payables consumed $6.2 million, and accruals and other items consumed $57.0 million. Inventory increased from $631.8 million at March 31, 2026 to $737.0 million at September 30.

Analytical inference: operating profit and cash generation are directionally consistent, but quarterly working capital makes a single period noisy. Restructuring also complicates comparability: fiscal 2027 restructuring charges included $19.1 million in operating expenses, with additional product-rationalization charges recorded in cost of revenue. Those charges are real economic costs and should not simply be ignored when judging sustainability.

Business Quality, Moat, and Industry Position

The moat evidence is primarily regulatory, technical, and service-based rather than network-driven. STERIS holds 606 U.S. patents and 2,402 patents in other jurisdictions, alongside approximately 2,079 trademark registrations. It sells infection-prevention systems into regulated healthcare and life-science environments, where product performance, validation, and customer workflows may create qualification barriers. It also supports installed equipment through maintenance, repair, process validation, and outsourced reprocessing.

AST’s global contract-sterilization network is strategically important because its facilities support medical-device and pharmaceutical manufacturers through testing and sterilization. The company also reports expanding irradiation capacity using accelerator-based technology to mitigate cobalt-60 supply risk. Nevertheless, AST competes with Sterigenics, smaller contract sterilizers, equipment makers, and manufacturers that sterilize in-house; Healthcare and Life Sciences also face large diversified competitors and focused specialists.

The most credible durability mechanism is the installed base: once a hospital or manufacturer validates equipment, chemistries, or a reprocessing workflow, changing supplier can involve testing, training, operating, and regulatory costs. That does not guarantee pricing power. Customers can negotiate, insource, switch technologies, or choose competitors offering lower lifecycle costs. AST’s facility footprint may be harder to replicate than a product, but it requires capital and regulatory operations, and the available evidence does not establish utilization, capacity elasticity, or segment profitability.

For supply-chain analysis, STERIS is primarily a downstream and midstream provider to healthcare, medical-device, and pharmaceutical customers. Its upstream inputs include raw materials, subassemblies, components, ethylene oxide, and cobalt-60. It says most supplies are available from several suppliers in sufficient quantities, but certain inputs have few suppliers or regional single sourcing. This supports a classification of important participant rather than proven core bottleneck. strategic importance scores 3 of 5: regulation, qualifications, and infrastructure support defensibility, but substitutability, utilization, concentration, and value-capture evidence remain incomplete.

Management and Capital Allocation

Observable conduct is mixed but generally disciplined. During the first six months of fiscal 2027, STERIS completed three tuck-in Healthcare acquisitions for aggregate consideration of approximately $17.3 million, a small amount relative to the $10.714 billion balance sheet. It also announced manufacturing consolidation and organizational optimization plans, with expected cash costs that extend into later fiscal years.

Shareholder distributions increased. During the second quarter, STERIS spent a calculated $100.4 million on repurchases and paid $67.0 million in dividends. For the six months, the derived figures were $215.9 million of repurchases and $128.4 million of dividends. Outstanding shares declined from 97.8 million at March 31, 2026 to 97.1 million at September 30, while diluted weighted-average shares fell 1.2% year over year to 97.6 million in the latest quarter.

The largest capital-allocation question is not the tuck-in acquisitions. STERIS expects to incur approximately $2.0 billion of additional debt to finance the pending Xodus Medical acquisition, beyond approximately $1.9 billion already outstanding at September 30, 2026. The filing warns that permanent financing terms may be unfavorable, a bridge facility could be shorter and costlier, and debt service depends partly on the acquired business meeting anticipated results.

Culture cannot be judged fully from public filings. The company’s effective disclosure controls, candor in quantifying restructuring and acquisition risks, and willingness to disclose impaired restructuring plans are observable positives. Whether management chooses durable reinvestment over debt-fueled expansion—and whether incentives reward per-share value rather than asset size—remains a judgment. Stock-based compensation was $21.7 million in the quarter and $63.1 million on a trailing-twelve-month basis, a real shareholder cost even though it is added back in operating cash flow.

Valuation and What the Market Already Expects

As of November 6, 2026, the share price was $254.55 and market capitalization was $24.819 billion. Against trailing free cash flow of $937.2 million, the equity cash-flow yield is approximately 3.8%. This is not a distress valuation and leaves limited protection if growth slows, margins compress, or acquisition financing becomes more expensive.

The market appears to require operating normalization rather than merely accounting earnings: sustained double-digit free-cash-flow growth in the near term, high-teen or better margins, and disciplined conversion of the acquired platform into cash. That burden is qualitatively consistent with the price because the valuation must also absorb additional acquisition debt and integration risk.

The enterprise-to-equity bridge uses the September 30, 2026 balance sheet: $531.1 million of cash and equivalents less total debt of $1.893 billion produces a net-debt adjustment of $1.362 billion. Total debt comprises $243.1 million of short-term borrowings and $1.650 billion of long-term debt including current maturities. Current debt was not separately available, and no unexplained reconciliation is invented.

The dated market capitalization materially exceeds the base scenario. Therefore, STERIS does not pass a Graham-style price test: a high-quality business does not become a margin-of-safety purchase simply because its products are essential or its recent quarter was strong. The price requires favorable assumptions across a long forecast horizon.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is reported operating cash flow less reported total capital expenditure: an accounting cash-flow proxy, not normalized sustainable earnings or maintenance-capex owner earnings. Every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and the supplied same-date balance-sheet adjustment. The supplied current cash and debt inputs reconcile to the dated adjustment shown below. Missing inputs are never treated as zero; an unavailable bridge would block this calculation. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 9.4% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. For positive scenario equity values, negative margin of safety means the current market capitalization exceeds the scenario value. For zero or negative scenario equity values, a margin-of-safety percentage is not meaningful; the obligations exhaust the modeled enterprise value.

Five Value-Investing Lenses

Benjamin Graham Lens

STERIS has meaningful financial substance: $7.257 billion of shareholders’ equity, $531.1 million of cash, positive operating cash flow, and a diversified customer base by segment. But those facts do not create downside protection at this price. The balance sheet carries $1.893 billion of debt, and the pending acquisition is expected to add approximately $2.0 billion. Graham’s discipline separates a sound investment from a sound company: the November 6 price requires sustained growth, while the base valuation remains well below it. On price alone, STERIS fails the margin-of-safety floor.

Benjamin Franklin Lens

The Franklin application is thrift, compounding, and opportunity cost. STERIS generates meaningful cash and returns some to shareholders, but buying shares at elevated prices can consume future returns even when the business performs well. During the first six months of fiscal 2027, the company committed substantially more to repurchases and dividends than to tuck-in acquisitions, yet debt-funded expansion is increasing the capital burden. The disciplined choice is to demand a higher prospective yield or evidence that acquisition returns will exceed the cost of capital, rather than reward headline growth.

Warren Buffett Lens

The owner-earnings test starts with the $937.2 million trailing accounting free-cash-flow proxy, operating cash flow less capital expenditure. This is not Buffett-style owner earnings because maintenance capital is not separated, stock compensation is not fully treated as a cash cost, and restructuring and acquisition economics require judgment. Capital allocation is mixed: modest tuck-ins and a declining share count help per-share economics, while $2.0 billion of expected acquisition debt raises the bar for future owner earnings. A wide moat is plausible, but the moat must produce durable per-share cash rather than merely defend market share.

Charlie Munger Lens

Munger’s lens turns the thesis upside down. Rather than asking whether STERIS can grow, it asks how the company could destroy value. Restructuring could fail to deliver expected capacity and efficiency; financing could become expensive; competitors could pressure pricing; or acquisition integration could consume management attention. The most likely wrong assumption is that a diversified portfolio and regulated end markets automatically protect margins and cash conversion. Incentives also matter: executive share sales and equity compensation should be tested against whether management is prioritizing per-share value. Inversion favors waiting for clearer acquisition economics and a less demanding price.

Li Lu Lens

STERIS is within a circle of competence when analyzed as a provider of infection-prevention products, regulated sterilization infrastructure, and lifecycle services. Its culture appears operationally serious, with measurable restructuring, disclosed costs, and effective controls, but deep customer-reference evidence and management-history evidence are not available. Durable advantage likely comes from regulatory qualification, installed-base relationships, technical know-how, and service integration rather than a single brand. Permanent-loss risk lies in leverage, acquisition execution, technological disruption, and paying too much for durable—but finite—competitive advantages. A strong franchise alone does not overcome valuation risk.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

At least three observable thesis breakers should govern future decisions. First, if organic revenue growth slows materially while gross or operating margins decline, the premise that STERIS combines durable growth with resilient economics would weaken. Second, if operating cash flow repeatedly trails net income because inventory, receivables, or other working capital absorbs cash, the $937.2 million trailing free-cash-flow proxy would prove poorly normalized. Third, if acquisition financing approaches or exceeds the disclosed approximately $2.0 billion without convincing cash-flow progress, leverage could impair flexibility and permanently weaken equity value.

A fourth breaker would be recurring service or consumable weakness, price pressure, or customer insourcing that reduces revenue while capacity remains in place. Observable indicators would include slower segment growth, declining service economics, excess or obsolete inventory, and customer concentration emerging in filings. A fifth is acquisition failure: regulatory delay, unfavorable financing, weak integration, or failure to realize the disclosed benefits.

The most likely wrong assumption is that recent revenue and operating-income growth will persist without interruption through a debt-funded expansion. Opportunity cost is substantial: owning a richly valued company means accepting lower prospective cash yields and substantial terminal-value dependence rather than preserving capital for less demanding assets. The conclusion would improve if the price fell enough to create a margin of safety, cash conversion strengthened, and acquisition financing produced visible per-share cash returns. It would worsen if debt rose before integration benefits appeared, margins compressed, or working capital absorbed another year of earnings.

Investment Conclusion

STERIS is a credible quality company with observable regulatory, technical, and installed-base advantages. The fiscal 2027 second quarter showed continued growth, higher operating profit, and positive cash conversion, but derived quarterly operating cash flow was nearly flat and restructuring complicates comparability. The November 6, 2026 market price demands sustained double-digit cash-flow growth, successful integration, and attractive acquisition financing.

The conclusion is Overvalued, not because the business is poor, but because price and prospective debt materially weaken downside protection. A Graham-style investor should wait for a lower entry price; a Fisher-style growth investor should still demand evidence that growth quality, cash conversion, and capital allocation can withstand the Xodus acquisition. This analysis is for educational use only and is not investment advice.